Wharton’s Jelly Derived Mesenchymal Stem Cells: Future of Regenerative Medicine? Recent Findings and Clinical Significance

Table 1

A summary of clinical trials of WJ-MSC registered on http://www.clinicaltrials.gov/ as of December 2014. ?: not mentioned.

Application	ClinicalTrials.gov identifier	Registered/phase	Number of cells	Regimen	Delivery route	Estimated enrollment
GvHD	NCT01754454	2012/1, 2	10^6/kg	4 at 1-week intervals	Intravenous	30
	NCT00749164	2008/1, 2	1-2 10^6/kg	?	Intravenous	20
Autism	NCT02192749	2014/1, 2	?	4 at 3-month intervals	Intravenous	20
Multiple sclerosis	NCT02034188	2014/1, 2	?	7 once per day	Intravenous	20
	NCT01364246	2011/1, 2	?	?	?	20
Hereditary cerebellar ataxia	NCT01489267	2011/2	10^7/2 mL	4 at 3–5-day intervals	Lumbar puncture	20
	NCT01360164	2011/1, 2	?	?	?	20
Amyotrophic lateral sclerosis	NCT01494480	2011/2	?	4 at 3–5-day intervals	Lumbar puncture	30
Hypoxic ischemic encephalopathy	NCT01962233	2013/1	1–8 10^8	single dose	Intravenous	10
Alzheimer’s	NCT02054208	2014/1, 2	Low dose: 1 10^7/2 mL; High dose: 7.5 10^7/15 mL	3 at 4-week intervals	Intraventricular	40
	NCT01547689	2012/1, 2	0.5 10^6/kg	8 at 2-week interval	Intravenous	30
Spinal cord injury	NCT02237547	2014/1, 2	?	Multiple times over the course of one month	Intravenous and intrathecal	20
	NCT01393977	2011/2	?	?	Lumbar puncture	40
	NCT01873547	2013/3	?	?	Lumbar puncture	300
Cerebral palsy	NCT01929434	2013/3			Lumbar puncture	300
Severe aplastic anemia	NCT02218437	2014/4	0.5–1 10^6/kg	3 at 1-week intervals	?	20
	NCT01182662	2010/2	10^6/kg	2 at 3-month intervals	Intravenous	30
Myelodysplastic syndromes	NCT01129739	2010/2	10^6/kg	2 at 3-month intervals	Intravenous	30
Cardiopathy	NCT01739777	2014/1, 2	10^6/kg	Single dose	Intravenous	30
Dilated cardiomyopathy	NCT01219452	2010/1, 2	?	?	Intramuscular	30
Myocardial infarction	NCT01291329	2011/2	?	?	Intracoronary	160
Autoimmune hepatitis	NCT01661842	2012/1, 2	10^6/kg	3 at 4-week intervals	Intravenous	100
Lupus nephritis	NCT01539902	2012/2	?	?	Intravenous	25
Systemic lupus erythematosus	NCT01741857	2012/1, 2	?	?	?	40
Epidermolysis bullosa	NCT01033552	2009/2	?	?	Intravenous	75
Burns	NCT01443689	2011/1, 2	?	?	?	20
Diabetic foot ischemia	NCT01216865	2010/1, 2	5 10^7	?	Intramuscular	50
Osteoarthritis	NCT02237846	2014/1, 2	?	3 once daily or single dose	Intravenous or intra-articular	40
Type 1 diabetes	NCT01219465	2010/1, 2	2 10^7	Single dose	Intravenous	50
Type 2 diabetes	NCT01954147	2013/1, 2	?	?	Intravenous	100
	NCT01413035	2011/1, 2	10^6/kg	2 at 90-day intervals	Intravenous	30
Ulcerative colitis	NCT01221428	2010/1, 2	2 10^7 + 10^7	One week apart	Intravenous + mesenteric artery	50
Duchenne muscular dystrophy	NCT01610440	2012/1, 2	?	?	?	15
	NCT02235844	2014/1	?	?	?	1
Liver failure	NCT01724398	2012/1, 2	10^5/kg	4 at 1-week interval	Intravenous	120
	NCT01218464	2010/1, 2	5 10^5/kg	3 at 4-week interval	Intravenous	70
	NCT01844063	2013/1, 2	10^5, 10^6, or 10^7/kg	8 at 1-week intervals	Intravenous	210
Liver cirrhosis	NCT01224327	2010/1, 2	?	Single dose	Via hepatic artery	50
	NCT01233102	2010/1, 2	?	Single dose	Intravenous or via hepatic artery	200
	NCT01220492	2010/1, 2	5 10^5/kg	2 at 4-week intervals	Intravenous	45
	NCT01662973	2012/1, 2	10^6/kg	3 at 4-week intervals	Intravenous	100
	NCT01877759	2013/1, 2	?	6 at 1-week intervals	Intravenous	20
	NCT01342250	2011/1, 2	?	?	?	20
	NCT01728727	2012/1, 2	10^6/kg	Single dose	Via hepatic artery	240
Liver transplantation	NCT01690247	2012/1	10^6/kg	3 at 4-week intervals	Intravenous	50
Ischemic-type biliary lesions	NCT02223897	2014/2, 3	10^6/kg	4 at 1-week intervals; 5 at 4-week intervals	Intravenous	66
HIV infection	NCT01213186	2010/2	Low dose: 5 10^5/kg; High dose: 1.5 10^6/kg	At weeks 0, 4, 12, 24, 36, and 48	Intravenous	72
Rheumatoid arthritis	NCT01547091	2012/1, 2	×	4 at 3-month intervals	Intravenous	200
	NCT01985464	2013/1, 2	?	5 daily	Intravenous	20
Ankylosing spondylitis	NCT01420432	2011/1	10^6/kg	2 at 3-month intervals	Intravenous	10
Bronchopulmonary dysplasia	NCT01207869	2010/1	/kg	Single dose	Via endotracheal tube	10